The heavy burden of cervical cancer, rapidly growing geriatric population, and technological advancements in colposcopy are the key factors driving the growth of this market.
The Colposcopy Market is expected to reach USD 740.1 Million by 2023 from USD 532.6 Million in 2018, at a CAGR of 6.8%. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=210884594 Optical colposcopes are estimated to account for the largest share of the colposcopy market in 2018 The colposcopy market is segmented on the basis of instrument type into optical colposcopes and digital colposcopes. In 2018, the optical colposcope segment is expected to account for the largest share of the colposcopy market. The large share of this segment can be attributed to advantages such as easy installation and low cost of these instruments. The portable colposcopes are expected to account for the largest share of the global colposcopy market On the basis of instrument portability, the market is segmented into portable, fixed, and handheld colposcopes. The portable colposcopes segment is expected to account for the largest share of the market in 2018 and it is also expected to grow at the highest CAGR during the forecast period. The growth of this segment can be attributed to the advantages portable colposcopes offer, which include ease of installation and movement within medical settings, better result reproducibility, and the ability to produce high-definition images, and stable cervix examinations. North America is expected to command the largest share of the market during the forecast period. Based on region, the colposcopy market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is expected to dominate the colposcopy market in 2018 and this trend is likely to continue during the forecast period. The large share of this segment can primarily be attributed to the high burden of cervical cancer, availability of technologically advanced screening tools, the presence of major players in this region, and the presence of quality healthcare infrastructure. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=210884594 Key players in the Colposcopy market include DySIS (US), CooperSurgical (US), Atmos (Germany), Olympus (Japan), Karl Kaps (Germany), McKesson (US), Danaher (US), and Carl Zeiss (Germany).
0 Comments
Key factors such growing geriatric population, increasing number of hospitals in emerging markets, and high prevalence of chronic diseases are the major factors driving the growth of the needles market across the globe.
The Needles Market is expected to reach USD 8.47 Billion by 2022, at CAGR of 7.8% during the forecast period. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=223979930 Market Segmentation:- On the basis of type, the global needles market is segmented into two broad categories, namely, conventional needles and safety needles. The conventional needles market is estimated to command the larger share of the global needles market in 2017. The growing demand for biosimilar products, the increasing incidence of chronic disease, and the expanding injectables market are the key factors contributing to the growth of this market segment. Based on product, the market is segmented into suture needles, blood collection needles, ophthalmic needles, dental needles, insufflation needles, pen needles, and other needles. The needles market is segmented into hypodermic, intravenous, intramuscular, and intraperitoneal needles on the basis of delivery mode. The hypodermic needles segment is expected to account for the largest share of the needles market in 2017. Key Market Drivers: – 1 High Prevalence of Chronic Diseases 2 Growing Geriatric Population 3 Increasing Number of Hospitals in Emerging Markets 4 Increasing Demand for Vaccines Regional Analysis: - As of 2016, North America held the largest share of the global needles market, followed by Europe. Its dominant share is attributed to the rising incidence of chronic diseases, initiatives by different organizations for the reduction in blood borne infections and increasing prevalence of cardiovascular diseases. Request for Sample Pages: -https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=223979930 Top Key Players: - The key players in the global needles market are Hamilton Company (U.S.), Medtronic plc (Ireland), Becton, Dickinson and Company (U.S.), Stryker Corporation (U.S.), B. Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), Terumo Corporation (Japan), Novo Nordisk A/s (Denmark), Smiths Medical (U.K.), and Thermo Fisher Scientific (U.S.). The major factors driving the growth of this market include the growing need to curb increasing healthcare costs and a growing focus on patient-centric care delivery. Moreover, government initiatives for enhancing patient care & safety and government funding for healthcare interoperability are also boosting market growth.
The Healthcare Interoperability Solutions Market is expected to reach USD 4.2 billion by 2024 from an estimated USD 2.3 billion in 2019, at a CAGR of 12.6%. Ask for PDF Brochure: –https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17705847 Market Segmentation:- Based on type, the healthcare interoperability solutions market is segmented into software and services. The services segment is estimated to account for the largest market share in 2019. The large share of this segment can be attributed to the shifting era towards cloud computing and reduced operational costs for better and faster performance of business processes and applications. Based on software type, the Interoperability solutions Market is segmented into EHR interoperability solutions, lab system interoperability solutions, imaging system interoperability solutions, HIE interoperability solutions, enterprise interoperability solutions, and other interoperability solutions. The HIE interoperability solutions segment is expected to grow at the highest CAGR during the forecast period. Recent Developments:-
Regional Analysis:- North America is expected to account for the largest share of the Interoperability solutions Market in 2019, followed by Europe. The dominance of the North American region can be attributed to the rising demand for quality healthcare delivery, a need to curb increasing healthcare expenditure, and the implementation of favorable initiatives & regulations to improve the overall efficiency of healthcare organizations in the region. Request for Sample pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=17705847 Top Key Players:- The prominent players in the Interoperability solutions Market are Cerner Corporation (US), Infor, Inc. (US), Allscripts Healthcare Solutions, Inc. (US), Koninklijke Philips NV (Netherlands), InterSystems Corporation (US), Orion Health Group Limited (New Zealand), iNTERFACEWARE (Canada), Quality Systems, Inc. (US), OSP Labs (US), Epic Systems Corporation (US), ViSolve, Inc. (US), and Jitterbit (US). Proficiency testing forms an essential precondition for operational excellence and accreditation in several industries. This is one of the major factors driving the growth of the proficiency testing market, globally. Also, the stringent safety and quality regulations for food and pharmaceutical products and the increasing focus on water testing are the other major factors supporting market growth.
The Laboratory Proficiency Testing Market is projected to reach USD 1,103 million by 2024 from USD 800 million in 2019, at a CAGR of 6.6% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144227949 The cannabis/opioids proficiency testing segment is estimated to grow at the highest CAGR in the laboratory proficiency testing market, by industry, during the forecast period In the laboratory proficiency testing market, by industry, the cannabis/opioids proficiency testing segment is estimated to grow at the highest CAGR during the forecast period. Growth in this segment is primarily driven by the legalization of medical cannabis, growing number of cannabis testing laboratories, rising awareness about the medical use of cannabis, and the increasing availability of analytical testing instruments and software. The proficiency testing market for chromatography is estimated to grow at the highest CAGR in the laboratory proficiency testing market, by technology, during the forecast period In the laboratory proficiency testing market, by technology, the chromatography segment is expected to grow at the highest CAGR during the forecast period. Chromatography is used to carry out complicated separations like amino acid sequencing or pollutant separations, based on differential partitioning between the mobile and stationary phase. The advantages associated with chromatographic testing, such as the increased safety, reliability, and transparency of the pharmaceutical supply chain by testing the identity, strength, purity, quality, and potency of a drug product, and the growth in the pharmaceutical industry as a whole are the major factors driving the growth of this segment. The Asia Pacific region holds high growth potential in the laboratory proficiency testing market The Asia Pacific is considered to be the most attractive regional market for laboratory proficiency testing owing to the large base of manufacturers and research laboratories in the region. Also, the growing scientific base and research capabilities in several Asian countries; growth of the Asian pharmaceutical, food, and biologics markets; and the large base of CROs in the region are some of the other major factors driving market growth in the region. Request for Sample Pages :- https://www.marketsandmarkets.com/requestsampleNew.asp?id=144227949 The prominent players operating in the global laboratory proficiency testing market are LGC Limited (UK), Bio-Rad Laboratories (US), Randox Laboratories (UK), Merck (Germany), College of American Pathologists (US), American Proficiency Institute (US), Waters Corporation (US), QACS (Greece), FAPAS (UK), AOAC (US), Phenova Inc. (US), Weqas (Cardiff), Advanced Analytical Solutions, LLC (UK), Bipea (France), Absolute Standards Inc. (US), and NSI Lab Solutions (US). Market growth is primarily driven by factors such as growing production of large molecules and biologics, technological advancements in nanofibers, growth in the generics market, and regulatory mandates for cleanrooms in pharmaceutical production. Other factors supporting market growth include an increase in R&D spending by biopharmaceutical companies to offer a strong biologics pipeline. The global Pharmaceutical Filtration Market is poised to reach USD 22.71 Billion by 2021 from USD 13.73 Billion in 2016, at a CAGR of 10.6% from 2016 to 2021. Ask for PDF Brochure:-https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=209343847 The global pharmaceutical filtration market is segmented on the basis of product, technique, application, scale of operation, and region. On the basis of product, the pharmaceutical filtration market is segmented into membrane filters, prefilters and depth media filters, cartridge & capsule filters, single-use systems, filter holders, filtration accessories, and other products. In 2016, the membrane filters segment accounted for the largest share of the market. This segment is also expected to register the highest CAGR during the forecast period. The key factor driving the growth of the membrane filters segment is the ease of installation in large and small manufacturing facilities owing to the availability of a variety of pore and surface types. Based on application, the final product-processing segment is expected to register the highest CAGR during the forecast period owing to the rapidly growing biologics and generic drug production coupled with the presence of stringent regulatory guidelines to maintain a clean and safe manufacturing environment. North America accounted for the largest share of the global pharmaceutical filtration market in 2016, followed by Europe. Stringent regulatory guidelines to provide safe drugs is encouraging the use of pharmaceutical filtration products and the presence of a large number of market players are propelling the growth of the North American pharmaceutical filtration market. The Asian region is expected to register the highest CAGR in the forecast period. Growing investments in the biopharmaceutical industry and the rise in contract research and manufacturing organizations in emerging Asian countries are the key factors driving the growth of the Asian market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=209343847 The pharmaceutical filtration market is dominated by established players such as Merck KGaA (Germany), GE Healthcare (U.S.), Pall Corporation (U.S.), Parker Hannifin Corporation (U.S.), and Sartorius Stedim Biotech S.A. (France). The benefits of CRM software and a growing focus on patient engagement are the major factors driving the growth of the healthcare CRM market.
The report Healthcare CRM Market is projected to reach USD 17.4 billion by 2023 from USD 8.8 billion in 2018, at a CAGR of 14.6% during the forecast period. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=88873203 Market Segmentation: - Based on end user, the healthcare CRM market is segmented into healthcare providers, the life sciences industry, and healthcare payers. The healthcare providers segment is estimated to account for the largest share of the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Healthcare providers need to interact with multiple stakeholders, including patients, physicians, other referral healthcare organizations, healthcare payer organizations, pharmaceutical companies, and consumers/potential patients, and each requires unique CRM strategies and solutions. Moreover, there is a growing focus on patient engagement, which is again likely to drive the market for this segment. On the basis of component, the healthcare CRM market is segmented into software and services. The services segment is expected to dominate the healthcare CRM market in 2018. This segment is also expected to register the highest CAGR during the forecast period. Services form a large component of the healthcare CRM market primarily due to the indispensable role of service providers when it comes to the use of CRM solutions for healthcare. In terms of IT usage and skills, the healthcare industry is still in the nascent stage; it relies heavily on service providers for CRM-related services and support services, such as implementation, integration, training and education, maintenance, and technology upgrades. The recurring need for services such as software upgrades and maintenance is the key factor supporting the growth of this segment. Regional Analysis: - Geographically, the global healthcare CRM market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). North America is estimated to hold the largest share of the healthcare CRM market. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=88873203 Top Key Players: - The key players in the healthcare CRM market are Salesforce.com, Inc. (US), SAP SE (Germany), Oracle (US), Microsoft (US), IBM (US), Influence Health (US), SugarCRM (US), Accenture (Ireland), Healthgrades (US), and Infor, Inc. (US). The growing target patient population and the rising focus on minimally invasive surgical procedures over conventional surgery are the major factors driving the growth of this market.
The report Catheters Market is Projected to Reach USD 24.2 Billion by 2025, at a CAGR of 8.7% from 2020 to 2025 Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=6247803 In 2019, the cardiovascular catheters segment accounted for the largest share of the market. On the basis of type, the global catheters market is segmented broadly into cardiovascular, urological, intravenous, neurovascular, and specialty catheters. Cardiovascular catheters commanded the largest share of the catheters market in 2019 and are expected to grow at the highest CAGR during the forecast period. This is primarily attributed to factors such as the high incidence of CVD, the growing geriatric population, and increasing awareness regarding early diagnosis. These factors have resulted in an increase in cardiovascular surgeries, which positively impacts the cardiovascular catheters market. Hospitals to be the largest end users of catheters Based on end user, the catheters market is segmented into hospitals, long-term care facilities, diagnostic imaging centers, and other end users. In 2019, hospitals were the largest end users of catheters. This segment is expected to grow at the highest CAGR, majorly due to the high volume of target procedures performed in hospitals. The presence of big cath labs and electrophysiology labs in hospitals and a growing patient population are other key drivers of this market. The emergence of advanced diagnostic imaging catheters, coupled with the demand for minimally invasive procedures, is accelerating the adoption of catheters in hospitals. North America was the largest regional market for catheters in 2018 The catheters market has been divided into four major regions, namely, North America, Europe, the Asia Pacific, and the Rest of the World (RoW). North America accounted for the largest share of the global catheters market in 2019. This is attributed to various factors such as the large number of target procedures performed in the region, the presence of a well-established healthcare system, and investments by hospitals to upgrade & expand operating capabilities. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=6247803 Top Key Players:- The prominent players operating in this market include Medtronic (Ireland), Edwards Lifesciences Corporation (US), Teleflex Incorporated (US), Abbott (US), B. Braun Melsungen AG (Germany), Becton, Dickinson and Company (US), Boston Scientific Corporation (US), ConvaTec Group (UK), Coloplast (Denmark), Johnson & Johnson Services (US), Terumo Corporation (Japan), Hollister Incorporated (US), Stryker (US), Cook Medical (US), and Merit Medical Systems (US). The growth of the market is attributed favorable reimbursement scenario and strong government support in selected countries, technological advancements in insulin delivery devices, and growing diabetic population. Increasing research and development activities and increase in diabetes-related health expenditure in emerging economies are expected to offer significant growth opportunities for manufacturers in the coming years.
The Insulin Delivery Devices Market is expected to reach USD 17.8 billion by 2021 from USD 11.5 billion in 2016, at a CAGR of 9.1% during the forecast period. Ask for PDF Brochure :- https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=107632092 Key Market Drivers:- 1 Growing Diabetic Population 2 Technological Advancements in Insulin Delivery Devices 3 Favorable Reimbursement Environment and Government Support in Selected Countries 4 Conferences, Meetings, and Congresses to Create Awareness About Insulin Delivery Devices Market Segmentation:- Based on type, the insulin delivery devices market is categorized into pens, pumps, pen needles, syringes, and others (insulin inhalers, transdermal patches, and insulin jet injectors, among others). In 2016, the pens segment is expected to command the largest share of the insulin delivery devices market. The pens segment is further divided into reusable and disposable pens. The reusable pens segment is estimated to command the largest share of the insulin pens market in 2016. This large share can be attributed to lower price compared to disposable pens; availability of reimbursement in selected countries, and increasing adoption of insulin pens in the Asia-Pacific region. By end user, the insulin delivery devices market is segmented into patients/homecare and hospitals & clinics. The patients/homecare segment is estimated to command the largest share of the market in 2016 and is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be primarily attributed to the increasing diabetic population and rising healthcare expenditure. Regional Analysis: - In 2016, North America is expected to account for the largest share of the global insulin delivery devices market. North America’s leadership position in the market can be attributed to the rising prevalence of diabetes and favorable reimbursement scenarios in the US and Canada, awareness activities, venture capital investments and issuance of IPOs in the US, and regulations for the usage of safety-engineered needles in Canada. Request for Sample Pages:- https://www.marketsandmarkets.com/requestsampleNew.asp?id=107632092 Top Key Players :- The insulin delivery devices market is highly competitive with the presence of several small and big players. Some of the players in the insulin delivery devices market include Becton, Dickinson and Company (US), Novo Nordisk A/S (Denmark), Ypsomed Holding AG (Switzerland), Medtronic plc (Ireland), Animas Corporation (US), Tandem Diabetes Care, Inc. (US), Sanofi (France), Biocon Ltd. (India), Eli Lilly and Company (US), and Insulet Corporation (US). The rising incidences of chronic and infectious diseases, increasing awareness of health and fitness, as well as major technological advancements are key factors driving the IVD market in the U.S. However, the lack of sufficient budget and reimbursement for novel diagnostic tests are restraining market growth.
The U.S. In Vitro Diagnostics (IVD) Market is projected to reach USD 25.99 Billion in 2020 at a CAGR of 4.7% from 2015 to 2020. Ask for PDF Brochure: -https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=66290979 The U.S. IVD product & services market is broadly segmented into reagents, instruments, services, and data management software. The reagents segment accounted for the largest share of the U.S. IVD product & service market in 2014 and is expected to grow at a highest CAGR during the forecast period. The large share of this segment is primarily attributed to the accessibility of a wide range of reagents and the need for reliable, specific, and faster detection of chronic diseases and genetic disorders at early stages. On the basis of end user, the U.S. IVD market is segmented into hospital laboratories, clinical/independent laboratories, and others. In 2014, the hospital laboratories segment accounted for the largest share of the U.S. IVD market in the U.S. The high inpatient flow and ancillary outpatient flow in hospitals, increasing prevalence of chronic and infectious diseases, and growing number of accredited laboratories are key factors driving market growth in this end-user segment. The U.S. IVD market has been segmented into four regions namely, South, Midwest, Northeast, and West. In 2014, the South region commanded the largest share of the U.S. IVD market, followed by West. However, the Midwest region is expected to witness the highest growth largely driven by the increasing number of accredited laboratories, reimbursement by the Medicare, increasing demand for technologically advanced diagnosis devices, and growing spending capabilities of consumers on healthcare. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=66290979 Some major players in the U.S. IVD market are Roche Diagnostics Limited (Switzerland), Abbott Laboratories, Inc. (U.S.), Becton, Dickson and Company (U.S.), Johnson & Johnson (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Siemens Healthcare (Germany), Bio-Rad Laboratories, Inc. (U.S.), Sysmex Corporation (Japan), QIAGEN N.V. (Netherlands), Alere Inc. (U.S.), Ortho-Clinical Diagnostics Inc. (U.S.), and bioMérieux (France). Factors such as the growing prevalence of target diseases, the favorable reimbursement scenario in major markets, and advancements in technologies & designs of electronic drug delivery systems are driving the growth of the electronic drug delivery systems market during the forecast period. However, emerging economies such as China, India, Russia, and Brazil offer significant growth opportunities for players in the electronic drug delivery market.
The report Electronic Drug Delivery Systems Market is projected to grow at a CAGR of 8.7% during the forecast period to reach USD 11.9 billion by 2024 from USD 7.8 billion in 2019. Ask for PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=165758442 The electronic wearable infusion pumps segment accounted for the largest share of the electronic drug delivery systems market in 2018. This is primarily due to the rising prevalence of diabetes and the increasing availability of commercial infusion pumps for diabetes treatment. However, the high cost of electronic drug delivery devices, high acceptance of conventional devices, and lack of reimbursement for electronic drug delivery devices in developing countries could restrain the growth of this segment. The diabetes segment accounted for the largest share in 2018. This is primarily due to the high prevalence of diabetes across the globe and the greater availability of electronic drug delivery devices, such as insulin pumps and injection pens, for diabetes in comparison to other therapeutic areas. For instance, according to the International Diabetes Federation, in 2017, almost 425 million people were suffering from diabetes worldwide; this is expected to increase to 629 million by 2045. In 2018, North America dominated the electronic drug delivery systems market, followed by Europe. High burden of target diseases, favorable reimbursement scenario, and the presence of major market players in this region are the factors propelling the growth of the market. For instance, in April 2018, AstraZeneca (UK) received OTC clearance for its SmartTouch for Symbicort (an electronic inhaler) and launched this product in the US market. Similarly, in December 2017, Companion Medical (US), launched InPen (an electronic injection pen) in the US. Request for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=165758442 Top Key Players:- The prominent players in the electronic drug delivery systems market are Insulet Corporation (US), Bayer AG (Germany), Medtronic (Ireland), Novo Nordisk A/S (Denmark), Companion Medical (US), F.Hoffmann-La Roche Ltd (Switzerland), United Therapeutics Corporation (US), AstraZeneca (UK), Tandem Diabetes Care (US), Merck Group (Germany), and Amgen (US). |
AuthorWe are providing and consulting the healthcare Industry Research Report. Archives
March 2022
Categories |